Perspective Therapeutics: announces updated interim Phase 1/2a results

What happened

• Perspective Therapeutics, Inc. announced on Oct 23, 2026 that it issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors. The results are being presented at the European Society for Medical Oncology Congress 2026 taking place Oct 23-27, 2026 in Madrid, Spain. The press release and presentation are included with the 8-K.

Key details

• Investigational agent: [212Pb]VMT-α-NET; trial stage: Phase 1/2a; target population: unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.
• Announcement date: Oct 23, 2026; presentation venue and dates: ESMO Congress 2026, Madrid, Oct 23-27, 2026.
• The company issued a press release and posted a presentation to its website, and those materials were filed with the 8-K.

Why it may matter

• The filing reports Item 8.01 (other events), covering the company’s announcement of updated interim clinical trial results, and Item 9.01, which attaches related exhibits. A filing does not show why the insider traded or why the company acted.